Meridian Bioscience
78 articles about Meridian Bioscience
-
Meridian Bioscience Drives Democratization of Next-Generation Sequencing (NGS) with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits
4/10/2024
The Life Science division of Meridian Bioscience, Inc. has announced the launch of a comprehensive menu of glycerol-free NGS enzymes for use in all steps of a Next Generation Sequencing ("NGS") workflow.
-
Meridian Bioscience Senior Director of R&D, Dr. Dan (Dror) Siman-Tov, to Spotlight Lateral Flow Innovations at the Advanced Lateral Flow Conference 2024
2/12/2024
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, is proud to announce that Dr. Dan Siman-Tov, Ph.D., MBA, Senior Director of R&D, Diagnostics, will be presenting at the Advanced Lateral Flow Conference 2024.
-
Meridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to Sustainability
11/28/2023
Meridian Bioscience, Inc. has been awarded the distinguished EcoVadis Bronze Medal in recognition of the commitment to its sustainable business practices.
-
Meridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA Flex
7/25/2023
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools.
-
Meridian Bioscience Sets a New Sustainability Standard in Diagnostic Assay Development with the Launch of Two New Animal-Free Immunoassay Interference Blockers
7/24/2023
The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced the launch of two new immunoassay interference blockers, K-Block™, and Mouse-Free IgG.
-
Meridian Bioscience Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay
4/19/2023
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) had granted clearance for the company's new Curian® Shiga Toxin assay.
-
SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience
1/31/2023
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian.
-
Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger
12/12/2022
Meridian Bioscience, Inc. announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023.
-
MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS
11/22/2022
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022.
-
MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS
8/5/2022
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022.
-
Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay
7/29/2022
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene ® SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA).
-
Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction
7/7/2022
Meridian Bioscience, Inc and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.
-
Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter
7/7/2022
Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022.
-
Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays
6/20/2022
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sample-specific master mixes, Lyo-Ready™ Direct DNA qPCR Stool Mix, and Lyo-Ready™ Direct RNA/DNA qPCR Stool Mix.
-
Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests
5/26/2022
Meridian Bioscience, Inc. announced today that its inhibitor-tolerant qPCR master mixes are ideal for the development of fast, accurate and highly sensitive qPCR monkeypox virus (monkeypox) molecular diagnostic tests.
-
Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference
5/23/2022
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced its participation in the 2022 H.C. Wainwright Global Investment Conference.
-
Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays
5/17/2022
Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the continued expansion of its isothermal amplification product line with the launch of two new innovative master mixes, Lyo-Ready™ Direct DNA LAMP Saliva Mix and Lyo-Ready™ Direct RNA/DNA LAMP Saliva Mix.
-
Meridian Bioscience Reports Record Second Quarter Fiscal 2022 Operating Results
5/6/2022
Meridian Bioscience, Inc. announced financial results for the second quarter ended March 31, 2022.
-
Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities
5/2/2022
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.
-
Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter
4/7/2022
Meridian Bioscience, Inc. today provided preliminary net revenues results for its second quarter of fiscal 2022.